# Clinical Trials Data EGFR - Document 22

# Combination of Chemotherapy and Gefitinib as First-line Treatment

## Clinical Trial: https://clinicaltrials.gov/study/NCT02148380

"eligibilityCriteria": "Inclusion Criteria:\n\n1. Signed informed consent\n2. Age \\>=18 years\n3. Histologically documented, unresectable, inoperable, locally advanced, recurrent or metastatic Stage IV Non-Small Cell Lung Cancer (NSCLC)\n4. A cytologic diagnosis is acceptable (i.e., FNA or pleural fluid cytology)\n5. Measurable or non-measurable disease\n6. Able to comply with study and follow-up procedures\n\nExclusion Criteria:\n\n\* Evidence of small cell, carcinoid, or mixed small cell/non-small cell histology\n\* Malignancies within 3 years except for adequately treated carcinoma in situ of -the cervix or basal or squamous cell skin cancer\n\* Symptomatic or untreated brain metastases\n\* Prior systemic chemotherapy for NSCLC\n\* Unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months prior to Day 1, or serious cardiac arrhythmia requiring medication (patients with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia, are eligible)\n\* History of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the patient at high risk from treatment complications\n\* Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, or prior surgical procedures affecting absorption\n\* Pregnancy or lactation",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
The provided information doesn't explicitly exclude patients with EGFR mutations. A patient with an EGFR mutation \*could\* be eligible if they also meet \*all\* of the inclusion criteria and \*none\* of the exclusion criteria. Specifically, they would need to have Stage IV NSCLC and not have any of the listed exclusionary conditions (prior chemo, uncontrolled systemic disease, etc.).  
  
It's important to note that many clinical trials for NSCLC, \*especially\* those involving novel treatments, often \*focus\* on specific genetic profiles like EGFR mutations. While this trial doesn't exclude them, the absence of specific mention of EGFR status suggests it might not be the primary focus. Therefore, a patient with an EGFR mutation might be better suited for a trial specifically designed for patients with that mutation, where they're more likely to receive a targeted therapy.